Pediatric Phase I/II study
Dovitinib pediatric study
Explore the study design, clinical focus and academic partners.
Phase I/II
About the study
Osteosarcoma
Led by SickKids and Children’s Cancer Institute
Study design
A multinational Phase I/II study of dovitinib, including evaluation in combination with standard chemotherapy, within the OPTIMISE collaboration.
Clinical focus
The study focuses on osteosarcoma. The broader development rationale considers the relevance of the pathways targeted by dovitinib across pediatric bone sarcomas.
What the study aims to learn
Establish tolerable dosing alone and in combination, look for early signals of activity, and evaluate biomarkers that could inform future development.
Trial leadership · Daniel Morgenstern, MD, PhD, and David Ziegler, MD, PhD
Explore our pipeline →